RARE PHOTOS: Cipla | Vintage Vibes

Cipla expects US business to draw support from upcoming product pipeline

Cipla reported a significant decline in its consolidated net profit for the second quarter of FY27. The company's North American revenue fell by 19% due to increased competition impacting sales of generic Revlimid. However, Cipla anticipates that its upcoming product pipeline will support performance in North America. In India, domestic…

The Economic Times · Oct 27

Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%

Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-year decline in revenue from operations, totaling Rs 7,404 crore. Additionally, a significant 26.7% decrease in EBITDA resulted in a lower margin of 18.7%. Nonetheless, Cipla's One…

The Economic Times · Oct 27

CPHI Milan: Beyond generics, how Indian pharma is rewriting its global playbook

At CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated products to expand their global footprint as geopolitical and supply-chain risks reshape the industry.

The Economic Times · Oct 8

Stocks in news: PB Fintech, LIC, Trent, Ola Electric, and Cipla

In a day of mixed economic signals, Indian markets displayed notable volatility before settling at a flat close. PB Fintech enjoyed a substantial rise in profits thanks to robust growth in insurance premiums. ONGC is also gearing up to ink deals with Venezuela for managing oil blocks. Simultaneously, Ola Electric…

The Economic Times · Aug 6

Nifty Q1 earnings grow 11% to beat estimate, says Motilal Oswal; picks Bharti Airtel, SBI, ICICI Bank among top bets

Nifty companies have posted a stronger-than-expected start to Q1 earnings, with profits of 39 reporting constituents rising 11% YoY, beating Motilal Oswal’s 7% estimate. Reliance Industries, JSW Steel, ICICI Bank, Bajaj Finance and Axis Bank drove 59% of incremental earnings growth, while InterGlobe Aviation, ITC, Dr Reddy’s, Cipla and Maruti…

The Economic Times · Aug 3

Stocks in news: Infosys, Cipla, Meesho, Suzlon Energy, IndiGo, NTPC

Markets extended their losing streak for a fourth consecutive session. Infosys reported a 12% year-on-year profit growth in its first quarter. Cipla's net profit fell 39% due to weakness in its North America business. IndiGo reported a loss of Rs 238 crore in its first quarter. Several other companies will…

The Economic Times · Jul 24

Cipla Q1 Results: Cons profit drops 39% YoY to Rs 789 crore; revenue rises marginally

Cipla Q1 Results: Pharma major Cipla reported a 39% year-on-year decline in Q1FY27 consolidated net profit to Rs 789 crore, mainly due to a high base, while revenue from operations rose a modest 2.3% to Rs 7,119 crore. The company's EBITDA also declined, with margins contracting sharply compared with the…

The Economic Times · Jul 23

Stocks in news: Infosys, IndusInd Bank, Eternal, Adani Green, Dr Reddy's

Indian markets experienced a decline on Wednesday due to global and geopolitical concerns. IndusInd Bank reported a significant profit increase while Eternal saw substantial net profit growth. BPCL, however, posted a considerable loss in the first quarter. Adani Green announced a moderate profit rise, and Dr Reddy's profit declined. Several…

The Economic Times · Jul 23

Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investors

Donald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analysts believe the long-term impact could be limited, citing India's manufacturing cost advantage, US-based production facilities of several drugmakers and uncertainty over how and when the tariffs will be implemented.

The Economic Times · Jul 22

Indian pharma firms may yet survive Trump's 200% tariff bombshell

Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say the long-term impact may be limited. India's cost advantage, America's dependence on imported generics and lengthy US factory approval timelines could make large-scale manufacturing shifts difficult despite Trump's…

The Economic Times · Jul 22